Research programme: cancer vaccines - Bio-Technology General/YedaAlternative Names: Research programme: cancer vaccines - BTG/Yeda
Latest Information Update: 22 Dec 2000
At a glance
- Originator Savient Pharmaceuticals; Yeda
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Dec 2000 Discontinued-Preclinical for Cancer in Israel (Unknown route)
- 22 Dec 2000 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 02 Aug 1999 Preclinical development for Cancer in USA (Unknown route)